Amarin Corporation PLC Release: AMR101 Phase 3 Study Data in Patients With Diabetes Mellitus (Type 2) to be Presented at the American Diabetes Association’s 72nd Scientific Sessions

BEDMINSTER, N.J., and DUBLIN, Ireland, June 4, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, today announced that data from the AMR101 pivotal Phase 3 ANCHOR study will be presented in a poster at the American Diabetes Association’s (ADA) 72nd Scientific Sessions at the Pennsylvania Convention Center in Philadelphia, Pennsylvania on June 9, 2012.